The board of directors of Consun Pharmaceutical Group Limited announced that the Company has received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration in relation to the approval of the clinical trial application for SK-07 injection. In accordance with the Drug Administration Law of the People's Republic of China and the relevant regulations, upon review, the application for clinical trial of SK-07 injection, which was accepted for processing on 17 January 2023, meets the relevant requirements for drug registration and it is approved that the clinical trial of this product can be commenced. Indication for the application: treatment of uremia pruritus.

Drug name: SK-07 injection; Application: Registration of clinical trial of pharmaceutical product; Acceptance number: CXHL2300090.